newsfilter
← Latest News
GlobeNewswire·

Codiak BioSciences Reports Second Quarter 2022 Financial Results and Operational Progress

– Reported platform-validating initial data from Phase 1 studies of exoSTING™ and exoIL-12™; plans to initiate Phase 2 studies for both programs in 1H 2023 – – Initiated patient dosing in Phase 1 clinical trial of exoASO™-STAT6 in patien